94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CASE REPORT article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1498701
This article is part of the Research Topic Advancing NSCLC Treatment: Overcoming Challenges in Immune Checkpoint Inhibitor Therapy View all 5 articles
Tislelizumab-induced type 1 diabetic ketoacidosis in a patient with small cell lung cancer: a case report
Provisionally accepted- 1 Changzhou Traditional Chinese Medicine Hospital, Changzhou, Jiangsu Province, China
- 2 Suzhou Municipal Hospital, Suzhou, Jiangsu Province, China
This report presented a case of 71-year-old man diagnosed with extensive-stage small cell lung cancer (ES-SCLC) who developed type 1 diabetic ketoacidosis (DKA) after 3 cycles of tislelizumab plus chemotherapy for the first time. The patient had no history of diabetes mellitus (DM). According to medical history and laboratory examination, the case was definitely diagnosed new-onset type 1 diabetic ketoacidosis induced by tislelizumab, a kind of immune checkpoint inhibitor. Despite the incidence of immune checkpoint inhibitor-induced type 1 diabetes mellitus (ICI-T1DM) is rare, the development of ICI-T1DM, especially type 1 diabetic ketoacidosis is life-threating without blood glucose monitoring and insulin therapy. Early identification of hyperglycemia and C-peptide persistence, as well as routine blood glucose monitoring during ICI treatment is essential to avoid lethal endocrine immune-related adverse event (irAE).
Keywords: tislelizumab, Immune-related adverse event, type 1 diabetes mellitus, Diabetic Ketoacidosis, Small Cell Lung Cancer
Received: 19 Sep 2024; Accepted: 17 Feb 2025.
Copyright: © 2025 Zhu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Wen-jie Wang, Suzhou Municipal Hospital, Suzhou, Jiangsu Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.